These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
787 related articles for article (PubMed ID: 33986723)
1. Immune Landscape of Thyroid Cancers: New Insights. Menicali E; Guzzetti M; Morelli S; Moretti S; Puxeddu E Front Endocrinol (Lausanne); 2020; 11():637826. PubMed ID: 33986723 [TBL] [Abstract][Full Text] [Related]
2. Immune Cell Confrontation in the Papillary Thyroid Carcinoma Microenvironment. Xie Z; Li X; He Y; Wu S; Wang S; Sun J; He Y; Lun Y; Zhang J Front Endocrinol (Lausanne); 2020; 11():570604. PubMed ID: 33193087 [TBL] [Abstract][Full Text] [Related]
3. Immune and Inflammatory Cells in Thyroid Cancer Microenvironment. Ferrari SM; Fallahi P; Galdiero MR; Ruffilli I; Elia G; Ragusa F; Paparo SR; Patrizio A; Mazzi V; Varricchi G; Marone G; Antonelli A Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500315 [TBL] [Abstract][Full Text] [Related]
4. Immune landscape of papillary thyroid cancer and immunotherapeutic implications. Na KJ; Choi H Endocr Relat Cancer; 2018 May; 25(5):523-531. PubMed ID: 29507047 [TBL] [Abstract][Full Text] [Related]
5. Immune microenvironment in papillary thyroid carcinoma: roles of immune cells and checkpoints in disease progression and therapeutic implications. Zheng X; Sun R; Wei T Front Immunol; 2024; 15():1438235. PubMed ID: 39290709 [TBL] [Abstract][Full Text] [Related]
6. The role of immune cells and immune related genes in the tumor microenvironment of papillary thyroid cancer and their significance for immunotherapy. Li X; Jian J; Zhang A; Xiang JM; Huang J; Chen Y Sci Rep; 2024 Aug; 14(1):18125. PubMed ID: 39103463 [TBL] [Abstract][Full Text] [Related]
7. A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer. Han PZ; Ye WD; Yu PC; Tan LC; Shi X; Chen XF; He C; Hu JQ; Wei WJ; Lu ZW; Qu N; Wang Y; Ji QH; Ji DM; Wang YL JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38478516 [TBL] [Abstract][Full Text] [Related]
8. The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition. Varricchi G; Loffredo S; Marone G; Modestino L; Fallahi P; Ferrari SM; de Paulis A; Antonelli A; Galdiero MR Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412566 [TBL] [Abstract][Full Text] [Related]
9. Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment. Moretti S; Menicali E; Voce P; Morelli S; Cantarelli S; Sponziello M; Colella R; Fallarino F; Orabona C; Alunno A; de Biase D; Bini V; Mameli MG; Filetti S; Gerli R; Macchiarulo A; Melillo RM; Tallini G; Santoro M; Puccetti P; Avenia N; Puxeddu E J Clin Endocrinol Metab; 2014 May; 99(5):E832-40. PubMed ID: 24517146 [TBL] [Abstract][Full Text] [Related]
10. Significance of Immunosuppressive Cells as a Target for Immunotherapies in Melanoma and Non-Melanoma Skin Cancers. Fujimura T; Aiba S Biomolecules; 2020 Jul; 10(8):. PubMed ID: 32707850 [TBL] [Abstract][Full Text] [Related]
12. Development and validation of a ferroptosis-related prognostic model for the prediction of progression-free survival and immune microenvironment in patients with papillary thyroid carcinoma. Huang Y; Xie Z; Li X; Chen W; He Y; Wu S; Li X; Hou B; Sun J; Wang S; He Y; Jiang H; Lun Y; Zhang J Int Immunopharmacol; 2021 Dec; 101(Pt A):108156. PubMed ID: 34624650 [TBL] [Abstract][Full Text] [Related]
13. Interactions between LAMP3+ dendritic cells and T-cell subpopulations promote immune evasion in papillary thyroid carcinoma. Wang Z; Ji X; Zhang Y; Yang F; Su H; Zhang H; Li Z; Zhang W; Sun W J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38816233 [TBL] [Abstract][Full Text] [Related]
14. Tumor immune microenvironment characteristics of papillary thyroid carcinoma are associated with histopathological aggressiveness and BRAF mutation status. Means C; Clayburgh DR; Maloney L; Sauer D; Taylor MH; Shindo ML; Coussens LM; Tsujikawa T Head Neck; 2019 Aug; 41(8):2636-2646. PubMed ID: 30896061 [TBL] [Abstract][Full Text] [Related]
15. METTL3 inhibition induced by M2 macrophage-derived extracellular vesicles drives anti-PD-1 therapy resistance via M6A-CD70-mediated immune suppression in thyroid cancer. Ning J; Hou X; Hao J; Zhang W; Shi Y; Huang Y; Ruan X; Zheng X; Gao M Cell Death Differ; 2023 Oct; 30(10):2265-2279. PubMed ID: 37648786 [TBL] [Abstract][Full Text] [Related]
16. CXCL5 expression is associated with active signals of macrophages in the microenvironment of papillary thyroid carcinoma. Le TN; Le MK; Dang MX; Kondo T Pathol Res Pract; 2024 Sep; 261():155474. PubMed ID: 39067172 [TBL] [Abstract][Full Text] [Related]
17. OGDHL closely associates with tumor microenvironment and can serve as a prognostic biomarker for papillary thyroid cancer. Mao M; Huang RZ; Zheng J; Liang HQ; Huang WH; Liu J; Li JH Cancer Med; 2021 Jan; 10(2):728-736. PubMed ID: 33405394 [TBL] [Abstract][Full Text] [Related]
18. Diagnostic and prognostic value of tumor-infiltrating B cells in lymph node metastases of papillary thyroid carcinoma. Yang Z; Yin L; Zeng Y; Li Y; Chen H; Yin S; Zhang F; Yang W Virchows Arch; 2021 Nov; 479(5):947-959. PubMed ID: 34148127 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of BRAF Sensitizes Thyroid Carcinoma to Immunotherapy by Enhancing tsMHCII-mediated Immune Recognition. Zhi J; Zhang P; Zhang W; Ruan X; Tian M; Guo S; Zhang W; Zheng X; Zhao L; Gao M J Clin Endocrinol Metab; 2021 Jan; 106(1):91-107. PubMed ID: 32936899 [TBL] [Abstract][Full Text] [Related]
20. VDR is a potential prognostic biomarker and positively correlated with immune infiltration: a comprehensive pan-cancer analysis with experimental verification. Xia X; Xu F; Dai D; Xiong A; Sun R; Ling Y; Qiu L; Wang R; Ding Y; Lin M; Li H; Xie Z Biosci Rep; 2024 May; 44(5):. PubMed ID: 38639057 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]